IVDs For Presence of Biothreats Should Evaluate Animal Specimens - FDA
This article was originally published in The Gray Sheet
Executive SummaryDevelopers of in vitro diagnostic tests for identification of biothreat agents should evaluate animal specimens and spiked plasma when seeking FDA approval, according to FDA's Microbiology Devices Panel.
You may also be interested in...
ANALYTE SPECIFIC REAGENT LABELING CHANGES DUE BY NOV. 1998 UNDER FDA FINAL RULE; ASR MANUFACTURERS TO BE RESPONSIBLE FOR PREMARKET FILINGS, FDAers SAY
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.